IBC Review and Consulting Services
No more waiting for a standing meeting. No submission deadlines. Responsive and flexible—only 10 business days or less from submission to institutional biosafety committee (IBC) review.
How Centralized IBC Review Can Benefit Gene Therapy Research
Gene therapy research is at the forefront of a coming boom in the clinical setting. Understand the growth, risks, and regulatory requirements here.
Preparing for Multisite Gene Therapy Studies
The fast and dramatic growth in the field of gene therapy is unprecedented, as the US FDA and regulatory agencies of several other countries have begun issuing approvals for licensed…
IBC-Ready™ Support
With IBC-Ready™, Advarra can help reduce confusion and administrative burden by coordinating with the sponsor, site personnel and local IBC(s) to complete local IBC submission forms.
Infection Control and Biosafety in Gene Therapy Research
Gene therapy research has moved from the realm of science fiction to mainstream clinical research. The maturation of this field...
Integration Update: Leading Compliance Adherence
The Advarra team is proud to announce that all major integration activities are now complete. SOPs have been harmonized; staff...
An Introduction to Human Gene Transfer Research and Institutional Biosafety Committees (IBCs)
Advarra’s Director of Biosafety Services Daniel Eisenman discusses the basics of research involving genetic engineering and the role played by the IBC in conducting safe and responsible research.
Integration Update: Recent Milestones Completed
The Advarra team has worked to fully integrate our processes and policies to provide clients with unified capabilities and support...
Advarra Services Overview
Advarra's integrated research compliance solutions help make your research altogether better.
